Karuna and Incyte scrap programs; More cash for the SPACs

Karuna Therapeutics has built itself into a $2 billion company off the data of an old Eli Lilly drug, when combined with trospium chloride, showed in schizophrenia. For a while, the company hoped that it might also prove effective as a non-opioid treatment for pain.